CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Clinique Laboratories, LLC

Clinique Laboratories, LLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Clinique Laboratories, LLC, please visit www.clinique.com

Medical Transportation Management Incorporated

MTM is a medical and transportation management company whose mission is to partner with our clients in developing innovative solutions for accessing healthcare, increasing independence, and connecting community resources in the most cost-effective manner. To achieve our mission and overarching mission of communities without barriers, we leverage our core competencies in managing customer service operations and building provider networks. MTM provides management of transportation, care coordination through home and community based services, call center operations, ambulance claims, and functional assessments and travel training to state and county governments, Medicaid and Medicare managed care organizations (MCOs), third-party administrators, and healthcare providers.

DirectCompRx

DirectCompRx is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fruit Street

Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.

ViTel Net

ViTel Net is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.